Lymphoma
2,045
185
261
1,173
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
418 trials with published results (20%)
Research Maturity
1173 completed trials (57% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.9%
243 terminated out of 2045 trials
82.8%
-3.7% vs benchmark
9%
176 trials in Phase 3/4
36%
418 of 1173 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1173 completed trials
Clinical Trials (2045)
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma